Novo Nordisk began a Phase 1 study of an oral obesity-drug candidate it agreed to license from Lexicon Pharmaceuticals last year. The study is investigating the safety and tolerability of the drug, ...

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential ...

Designing effective lexicons is a critical component of any communications surveillance program, yet even mature teams encounter avoidable pitfalls that diminish accuracy, create operational strain, ...

THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and ...

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 ...

Lexicon’s pipeline includes drug candidates in discovery and development stages for neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolism. This funding comes as InvestingPro analysis ...

Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Subscribe to continue reading, or log in.

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

(Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, ...